AcadeMab Biomedical

Focus: AcadeMab Biomedical is a Taiwan-based antibody and mRNA drug developer founded in 2020, focused on gene therapy applications. The company operates as a pre-revenue biotech with minimal disclosed financials and a single Phase 1 oncology program.

Gene Therapy

Profile data last refreshed 1h ago · AI intelligence enriched 3w ago

Open Jobs

About AcadeMab Biomedical

AI assessmentNot Hiring

No open roles listed right now. Follow AcadeMab Biomedical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

RBC-SCAN

Diagnostic imaging (unspecified)

LOE Approaching

Sole marketed product with no disclosed revenue; approaching loss of exclusivity and poses minimal commercial relevance.

Products & Portfolio (1)

Help build intelligence for AcadeMab Biomedical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage platform play: founding team building a proprietary antibody/mRNA engine with gene therapy focus, offering significant upside equity and technical autonomy.
Emerging biotech hub: based in Taiwan's growing biotech ecosystem with lower cost-of-living and proximity to APAC manufacturing.
Scientific frontier: pre-clinical and Phase 1 stage allows hands-on involvement in foundational drug discovery and translational work.

Watch Out For

Zero active hiring and no disclosed funding: despite 2020 founding, company shows no open requisitions and financial runway is opaque; career stability cannot be assessed.
Minimal clinical validation: only one Phase 1 trial across entire pipeline and one aging marketed product (RBC-SCAN) approaching loss of exclusivity; no proof of clinical or commercial traction.
Pre-revenue with unknown cash: no published financials, clinical milestones, or funding disclosures make risk assessment impossible for job seekers.

Generated by Claude from AcadeMab Biomedical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Pipeline & Clinical Trials

AM-928

Advanced Solid Tumor

Phase 1

Clinical Trials (1)

NCT05687682Safety of AM-928 Infusion in Advanced Solid Tumors

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2020

Portfolio: 1 approved product, 1 clinical trial

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Portfolio Health

LOE Approaching1 (100%)

1 total products

Therapeutic Area Focus

Oncology

1 pipeline

Marketed

Pipeline